"J&J: Toughing Out The Drought" (The Corporation, Jan. 26, 2004)
In "J&J: Toughing out the drought" (The Corporation, Jan. 26), Johnson & Johnson's (JNJ
) drug-coated stent should have been described as being embraced by cardiologists rather than surgeons. The drug Risperdal was described as being developed by J&J's Centocor. It is actually a product of the Janssen Research Foundation, a different J&J unit. Also, it should be noted that final FDA approval of Topamax as a migraine treatment is still pending.
"What India Can Do To Catch Up With China" (Economic Viewpoint, Feb. 16, 2004)
Economic Viewpoint (Feb. 16), "What India can do to catch up with China" should have begun, "Many are predicting that China will be a dominant force in the 21st century..." (not "20th"). The error was made in the editing process, not by writer Gary Becker.
Copyright 2004, by The McGraw-Hill Companies Inc. All rights reserved.
Printer-Friendly Version
